

2 **Review**

3

4

5 **An update on alternatives to antimicrobial growth promoters for broilers**

6

7

8 Gerard Huyghebaert^{a,*}, Richard Ducatelle^b, Filip Van Immerseel^b

9

10

11 *^a Ministry of the Flemish Community, Institute Agriculture Fishery Research ILVO Animal*

12 *Nutrition Sciences, Scheldeweg 68, B-9090 Melle, Belgium.*

13 *^bDepartment of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine,*

14 *Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium.*

15

16

17

18

19 * Corresponding author. Tel.: +32 92522619; fax: +32 92522601.

20 *E-mail address: gerard.huyghebaert@ilvo.vlaanderen.be (G. Huyghebaert)*

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38
39
40

Abstract

41 Livestock performance and feed efficiency are closely interrelated with the qualitative and
42 quantitative microbial load of the animal gut, the morphological structure of the intestinal wall and
43 the activity of the immune system. Antimicrobial growth promoters have made a tremendous
44 contribution to the profitability in the intensive husbandry. As a consequence of the increasing
45 concern about the potential for antibiotic resistant strains of bacteria, the European Commission
46 decided to ban all commonly used feed antibiotics. There are a number of non-therapeutic
47 alternatives, including enzymes, (in)organic acids, probiotics, prebiotics, etheric oils and
48 immunostimulants. Their efficacy and mode of action is briefly described.

49

50 *Keywords:* Antimicrobial growth promoters; Alternatives; NSP-enzymes; Inorganic acids; Organic
51 acids; Probiotics; Prebiotics; Etheric oils; Immunostimulants; Broilers

52

53

54

55

56

57

58

59

60 **Introduction**

61 Antibiotics have been widely used in animal production for decades. Although some are
62 used therapeutically to improve the health and well-being of animals, a large portion was employed
63 for prophylactic purposes and to improve growth rate and feed conversion efficiency (as
64 antimicrobial growth performance promoters, or AGPs). However, due to the emergence of
65 microbes resistant to antibiotics which are used to treat human and animal infections, the European
66 Commission (EC) decided to phase out, and ultimately ban (January 1st 2006), the marketing and
67 use of antibiotics as growth promoters in feed (EC Regulation No 1831/2003¹). This political
68 decision was taken by invoking the precautionary principle: *‘Where there are threats of serious or*
69 *irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing*
70 *cost-effective measures to prevent environmental degradation’* (Principle 15 of the Rio Declaration,
71 1992²).

72

73 In other countries, such as the USA, consumer pressure is pushing the poultry industry to
74 rear animals without AGPs (Dibner and Richard, 2005; Castanon, 2007). AGP removal has led to
75 animal performance problems, feed conversion increases, and a rise in the incidence of certain
76 animal diseases, such as (subclinical) necrotic enteritis (Wierup, 2001; Dibner and Richards, 2005).
77 One disease syndrome that is clearly emerging in the EU broiler industry simultaneously with the
78 ban of growth promoting antibiotics is the so-called ‘dysbacteriosis’. This is a poorly described
79 condition of the gut and may be synonymous with conditions such as ‘wet litter’, ‘small intestinal
80 bacterial overgrowth’, ‘malabsorption’, ‘feed passage syndrome’ and others. The common clinical
81 denominator is thinning and ballooning of the small intestine, increased water content of faeces and
82 reduced digestibility of feed with indigested residues visible in the faeces.

83

84 The impact of phasing out of animal growth promoters could be minimised provided that
85 adequate attention is given to the implementation of alternative disease-prevention strategies and
86 management factors, such as alternative husbandry practices in food animal production. Indeed,
87 overall disease and performance problems have been rather limited, partly because ionophore
88 anticoccidials are still available, therapeutic antibiotic use (e.g. macrolides and penicillins) has
89 increased, and alternatives for AGPs have been empirically used such that those with the best
90 effects on performance are currently used as feed additives.

91

92 **Characteristics of good AGP alternatives**

93 Ideally, alternatives to growth promoters should have the same beneficial effect as AGPs. It is
94 however not totally clear how AGPs exert their beneficial action. The most well-known mechanism
95 to be proposed is that AGPs have an antibacterial action that favours performance in different ways:
96 (1) by reducing the incidence and severity of subclinical infections (George et al., 1982; Brennan et
97 al., 2003); (2) by reducing the microbial use of nutrients (Snyder and Wostmann, 1987); (3) by
98 improving absorption of nutrients because of thinning of the intestinal wall, and (4) by reducing the
99 amount of growth-depressing metabolites produced by Gram-positive bacteria (Feighner and
100 Dashkevicz, 1987; Knarreborg et al., 2004). The basis of this mechanistic explanation is that AGPs
101 do not exert growth-promoting effects in germ-free animals (Coates et al., 1963).

102

103 Although certain authors reason that AGPs are used in sub-therapeutic or sub-minimum
104 inhibitor concentration (MIC) doses and so any growth-inhibitory action is unclear (Niewold,
105 2007), clear shifts in the microbiota composition have been demonstrated when AGPs were added
106 to broiler feed (Pedroso et al., 2006; Wise and Siragusa, 2007). Indeed, sub-MIC concentrations do

¹ See: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:268:0029:0043:EN:PDF>

² See: <http://www.unep.org/Documents/Multilingual/Default.asp?DocumentID=78&ArticleID=1163>

107 not mean that growth-inhibition of certain bacterial species in the gut can be excluded but shifts in
108 microbiota composition can, at least in theory, explain the effects of the AGPs. Furthermore,
109 microbiota shifts can affect morphology of the gut wall and induce immune reactions that can have
110 effects on energy expenses of the host (Humphrey and Klasing, 2003; Teirlynck et al., 2009).

111

112 Niewold (2007) hypothesized that AGPs may be growth permitting by inhibiting the
113 production and excretion of cytokines by immune cells (macrophages), after AGPs accumulate in
114 these cells. Cytokine release would then lead to an acute phase response leading to loss of appetite
115 and muscle tissue catabolism (Niewold, 2007). Certainly inflammation leads to performance
116 decreases (Humphrey and Klasing, 2003), but equally AGPs may act by shifting the microbiota
117 composition towards one that is less capable of evoking an inflammatory response. AGPs could
118 also simply lower the total microbial load, leading to less inflammation and lower energetic cost for
119 the animal.

120

121 Whatever the mechanism of action of AGPs, the main characteristic of a good alternative from
122 a practical point of view is that it must improve performance at least as well as AGPs. Based on the
123 proposed mechanism of action of AGPs, both microbiota modulating and immunomodulatory
124 compounds could have potential. There are many possible ways microbiota modulating compounds
125 could influence the intestinal microbiota population without adding AGPs to the feed. The most
126 obvious method is the use of therapeutic doses of antibiotics under prescription, a practice that will
127 undoubtedly increase and (ironically) probably raise the likelihood of the emergence of resistant
128 human pathogens.

129

130 None of the non-antibiotic AGP alternatives suggested below is likely to compensate fully for
131 the loss of AGPs. It must be emphasised that some strategies will only help to compensate partially
132 (but will not replace) AGPs, and will work through indirect mechanisms. The list is by no means
133 exhaustive and there are also other products claiming to be of value in AGP-free diets.

134

135 **Some alternatives for AGPs and their mode of action**

136 *Exogenous enzymes*

137 Non-starch polysaccharides (NSPs) in animal feedstuffs are a complex group of components
138 differing widely in chemical composition, physical properties and physiological activity, many of
139 which have negative effects on growth and performance. NSPs include (hemi)celluloses, pectins
140 and oligosaccharides as well as arabinoxylans and β -glucans (consisting of either a more soluble or
141 a non-soluble fraction).

142

143 Different cereal types contain variable NSP levels with concomitant differences in chemical
144 composition. For example, maize contains almost exclusively insoluble NSPs, whereas wheat and
145 barley contain NSPs of which the ratio of soluble to insoluble is about 1/6. This ratio is about 3/4 in
146 rye, making this cereal one with particularly high levels of soluble NSPs (Choct, 2002).

147

148 The mechanism by which NSPs exert their anti-nutritive effects is complex, but their viscous
149 nature is considered a primary cause for their anti-nutritive effect in poultry. This is because the
150 increased bulk and viscosity of the intestinal contents decrease the rate of diffusion of substrates
151 and digestive enzymes and hinder their effective interaction at the mucosal surface (Choct et al.,
152 1996). NSPs also induce thickening of the mucous layer on the intestinal mucosa (Hedemann et al.,

153 2009) suggesting that the concentrations of soluble NSPs in wheat are inversely correlated with
154 their metabolisable energy (ME_N)-values in broiler chickens (Annison, 1991).

155

156 In addition to the direct effect of viscous NSPs on gut physiology and morphology, there
157 appear to be some indirect effects that could have important implications for the efficient use of
158 nutrients by the chicken (Dänicke et al., 1999). One such indirect effect may be related to
159 stimulation of fermentation of NSPs by the gut microbiota, leading to volatile fatty acid production
160 (VFA) in the small intestine. Under normal circumstances with low NSP-diets, facultative
161 anaerobes predominate in the chicken small intestine and nearly strict anaerobes make up the entire
162 caecal microbiota (Salanitro et al., 1978; Lu et al., 2003; Bjerrum et al., 2006). On a NSP-rich diet,
163 the VFA-concentration increases mainly in the distal ileal lumen due to excess fermentation
164 combined with a proliferation of the fermentative microflora with a rather limited effect on the
165 activity of the hindgut microbiota (Choct et al., 1996; 1999). Small intestinal fermentation indicates
166 competition with the host for digestible nutrients. Enzyme-free diets containing soluble-NSP rich
167 cereals (wheat) have been shown to induce lymphocyte infiltration in the gut wall and induce
168 apoptosis of epithelial cells much more than cereals such as maize that have low levels of soluble-
169 NSPs (Teirlynck et al., 2009).

170

171 Negative effects of diets with high NSP levels can be partly counterbalanced by adding AGPs
172 (Teirlynck et al., 2009). Without these, supplementing the NSP-rich diet with enzymes results in
173 both a reduction in ileal VFA-concentration and an elevation in caecal VFA-concentration (Choct et
174 al., 1996) as more 'low molecular weight' fermentable material is entering the caecum. Caecal
175 fermentation suggests the conversion of indigestible compounds into readily absorbable VFAs.

176

177 Dietary NSP-enzymes work by reducing the viscosity of the digesta in the small intestine, so
178 that digesta passage and nutrient digestion rate increase providing less substrate and less time for
179 the fermentation organisms to proliferate. This may restore the normal and efficient endogenous
180 enzymatic digestion of nutrients in the small intestine. The enzymes are partially counterbalancing
181 the adverse effects of soluble NSP on performance (Bedford and Classen, 1992).

182

183 It is not possible to measure the relative contribution following improved nutrient utilisation or
184 the 'selective' reduction in the microbial population (Smits and Annison, 1996). However, there is
185 evidence that the consequence of a NSP-mediated reduced rate of digestion is much more radical in
186 the presence of intestinal microbiota due to the degradation of both digestive enzymes and bile salts
187 and colonisation of the absorptive surface area (Smits and Annison, 1996). In the absence of
188 antimicrobial growth promoters (as in the European Union), there will be a greater response to
189 enzymes, particularly in less well-digested diets (Elwinger and Teglöf, 1991). Furthermore, NSP
190 degrading enzymes will also reduce the proliferation of pathogenic bacteria such as *Clostridium*
191 *perfringens* (Jackson et al., 2003). These days all broiler feed contains enzymes such as xylanases
192 and beta-glucanases that breakdown NSPs.

193

194 *Organic acids*

195 Organic acids have been shown to have beneficial effects on performance. Some (e.g. butyric
196 acid) also decrease the incidence of subclinical necrotic enteritis caused by *C. perfringens*, an
197 additional beneficial effect which is highly relevant for the poultry industry (Timbermont et al.,
198 2009). Organic acids are widely distributed in nature as normal constituents of plants or animal
199 tissues. They are also formed through microbial fermentation of carbohydrates predominantly in the
200 caeca of poultry (Van Der Wielen et al., 2000).

201

202 A wide range of organic acids with variable physical and chemical properties exists, of which
203 many are used as drinking water supplements or as feed additives (acidifiers). Many are also
204 available as sodium, potassium or calcium salts (and/or partially esterified). The advantage of salts
205 over acids is that they are generally odourless and easier to handle in the feed manufacturing
206 process owing to their solid and less volatile form. They are also less corrosive and may be more
207 soluble in water.

208

209 The mechanism of action of organic acids probably reflects their antibacterial nature, such as
210 decreasing the pH of drinking water and reducing the buffering capacity of the feed with subsequent
211 effect on the physiology of the crop and proventriculus (Thompson and Hinton, 1997; Van
212 Immerseel et al., 2006). The ability of organic acids to change from undissociated to the dissociated
213 form (depending on the environmental pH) enhances their antimicrobial effect. When the acid is in
214 the undissociated form it can freely diffuse through the semi-permeable membrane of the
215 microorganisms into the cell cytoplasm (Adams and Hall, 1988; Van Immerseel et al., 2006). Once
216 in the cell, where the pH is maintained near 7, the acid will dissociate and suppress bacterial cell
217 enzymes (e.g. decarboxylases and catalases) and nutrient transport systems. The efficacy of an acid
218 in inhibiting microbes is dependent on its pKa value, which is the pH at which 50% of the acid is
219 dissociated. Organic acids with higher pKa values are more effective antibacterial compounds and
220 their efficacy is generally improved with increasing chain length and degree of unsaturation.

221

222 In general, variables that influence antibacterial activity are (1) chemical formula, (2) pKa-
223 value of the acid, (3) chemical form (esterified or not, acid, salt, coated or not), (4) molecular
224 weight, (5) the micro-organism related MIC-value of the acid, (6) the nature of the micro-organism,
225 (7) animal species, and (8) the buffering capacity of the feed (Patten and Waldroup, 1988;

226 Thompson and Hinton, 1997). It is thus clear that each acid has its own spectrum of microbial
227 activity related to differences in both specific pH-range, membrane structure and in-cell physiology
228 of the microbiota species.

229

230 Blends of acids represent an array of pKa values and are used because of the broader spectrum
231 of activity. The physical form of the acids also plays a role in the AGP replacement effect. The
232 coating or micro-encapsulation of fatty acids with a progressive ‘slow release’ matrix is essential
233 for their anti-microbial activity throughout the distal part of the gastro-intestinal tract. Also additive
234 effects of acids are possible. There are indications that the medium chain fatty acids (with a chain
235 length between 8 and 12 carbon atoms, e.g. caproic acid, has a lower absorption rate because of the
236 higher molecular weight) may improve the efficacy of the short chain fatty acids. In the field,
237 mixtures of organic acids are mainly used, which makes their spectrum broader and combines the
238 good qualities of the different acids.

239

240 The possibility that providing additional organic acids in the feed may act as a rapidly
241 absorbed energy source cannot yet be ruled out. Moreover, there is some evidence of increased
242 growth of the gastro-intestinal mucosa in the presence of organic acids, particularly fatty acids such
243 as butyric acid. It has been well documented that butyric acid exerts a wide variety of effects on
244 intestinal function in rodents and humans, and these effects may also be present in livestock.
245 Indeed, butyric acid has been shown to be an important energy source for gut epithelial cells and to
246 stimulate epithelial cell proliferation and differentiation (Dalmasso et al., 2008). Butyric acid also
247 has well documented anti-inflammatory effects (Hodin, 2000) and has been shown to strengthen the
248 gut mucosal barrier by increasing production of antimicrobial peptides in mucous and by
249 stimulating the expression of tight junction proteins (Mariadason et al., 1997; Schaubert et al., 2003;
250 Bordin et al., 2004; Peng et al., 2007). Thus for some acids, especially butyric acid, not only

251 antibacterial but also host effects can play a role in the AGP-replacement effect. Whether other
252 acids, such as medium-chain fatty acids, have similar effects on host cell activities has not yet been
253 investigated.

254

255 *Probiotics or 'direct-fed microbials'*

256 Probiotics have been defined as '*mono- or mixed cultures of living microorganisms which*
257 *beneficially affect the host by improving the properties of the indigenous microbiota*' (Fuller, 1992).
258 The available probiotics can be classified into (1) 'colonizing' species, such as *Lactobacillus* and
259 *Enterococcus* spp., and (2) free flowing 'non-colonizing' species, such as *Bacillus* spp. (spores) and
260 *Saccharomyces cerevisiae*. Competitive exclusion (CE) describes the treatment of day-old chicks
261 with an undefined microbiota derived from adult animals resulting in colonisation resistance against
262 pathogenic microorganisms.

263

264 There is considerable variation in published studies that evaluate the effect of probiotic strains
265 on performance. It is not the aim of the current review to summarise these data but the search terms
266 PROBIOTICS, PERFORMANCE and POULTRY in Medline leads to numerous publications on
267 this issue. The differences in outcome are most likely due to differences in dose and nature of the
268 administered strains and their persistence (relative intestinal concentration), stability during feed
269 manufacturing (as well as in the gastro-intestinal tract), variation in the physiological state of the
270 bird, and the actual microbiota balance in the gut of the animal. The ideal probiotic should be an
271 image of the indigenous strains resistant to feed processing (a coating might be helpful, e.g. for
272 living yeast cells), as well as acidity, and the effects of bile salts and digestive enzymes. It must also
273 be rapidly proliferating. Bacteria intended for probiotic use should be screened for antibiotic
274 resistance to avoid any potential carriage of undesirable antibiotic resistance into the intestinal
275 environment.

276

277 The mechanism of action of probiotics as AGP replacers will depend on the nature of the
278 organism and is not always clear. The different bacterial species in the normal microbiota
279 (colonising on the epithelium of the digestive tract or occurring freely in the gut lumen) of the
280 broiler gut reach a typical equilibrium state after about a week post-hatch, and depends on many
281 factors including location in the gastro-intestinal tract, integrity of the intestinal mucosa and transit
282 time of the chymus (Van Der Wielen et al., 2000; 2002; Teirlynck et al., 2009).

283

284 The intestinal microbiota has a specific multifactorial 'barrier' impact, such as (1) induction of
285 anatomical and physiological changes in the intestinal cell wall structure, (2) immunological
286 modifications in the gut, and (3) enhancement of the bird's resistance to enteropathogenic bacteria,
287 such as *C. perfringens* (Nurmi and Rantala, 1973; Hofacre et al., 1998; La Ragione et al., 2004;
288 Kalliomaki et al., 2008; Ng et al., 2009). Depending on the probiotic strain, the mode of action
289 probably involves production of specific metabolites (short organic fatty acids, H₂O₂, intermediary
290 metabolites with antimicrobial activity), interaction with receptor sites, stimulation of the immune
291 system and some others (Madsen, 2001; Sherman et al., 2009).

292

293 The most well known group of probiotics are lactic acid bacteria. It has been shown that lactic
294 acid produced in vitro by lactic acid bacteria is used by the strictly anaerobic butyrate producing
295 bacteria of Clostridial clusters IV and XIVa for the production of large concentrations of butyric
296 acid (Duncan et al., 2004). This mechanism is called cross-feeding and is a further reason why
297 lactic acid bacteria administration can beneficially affect performance (see above in the section on
298 butyric acid).

299

300 *Prebiotics*

301 Prebiotics can be defined as non-digestible feed ingredients with selective effects on the
302 intestinal microbiota. Oligosaccharides are the main components and the range is diverse and may
303 be based on any of the hexose monosaccharides, including glucose, fructose, galactose and mannose
304 (Durst, 1996) with a polymerisation degree of between 2 and 20 monosaccharides. Grain legumes
305 are the most common natural sources of oligosaccharides, being present as raffinose, stachyose and
306 verbascose. 'Synthetic' oligosaccharides are derived from the direct polymerisation of disaccharides
307 or from the fractionation of both vegetable and microbial cells. Oligosaccharides such as
308 arabinogalactose, arabinoxylan and rhamnogalacturonose are derived from polysaccharides of
309 soybean (with about 3-5% galacto-oligosaccharides), wheat and fruit, respectively (Schols et al.,
310 1994; Huisman et al., 2001; Van Craeyveld et al., 2009)..

311

312 The mechanism of action of prebiotics as AGP replacers is dependent on the nature of the
313 compound. They are non-digestible feed ingredients that can have a beneficial action because of
314 selective stimulation of the growth or metabolic activity of a limited number of intestinal microbiota
315 species, such as *Bifidobacteria* and *Lactobacillus* spp. (Gibson and Roberfroid, 1995). Thus they
316 may have a similar mechanism of action as probiotics.

317

318 Conflicting results obtained with or without oligosaccharides that occur naturally in feed
319 ingredients (for example the raffinose series oligosaccharides) present an unclear scenario regarding
320 the effect of their inclusion in diets for broilers (Coon et al., 1990; Leske et al., 1991; Iji and Tivey,
321 1998); however, their nutritional impact cannot be separated from other anti-nutritive components
322 in the diet. The lack of any beneficial effect might be related to the non-specificity of the process of
323 hindgut fermentation. When ingested, prebiotics stimulate the growth and/or metabolic activity of

324 different bacterial species, including species that are both potentially harmful and beneficial
325 (Maczulak et al., 1993).

326

327 Results obtained from synthetic materials suggest some benefits using inulin and fructo-
328 oligosaccharides (FOS) that act as substrates for 'desired' microorganisms, for example
329 bifidobacteria (Waldroup et al., 1993; Iji and Tivey, 1998; Verdonk et al., 2005; Ramirez-Farias et
330 al., 2009), whereas manno-oligosaccharides (MOS) have receptor properties for fimbriae of *E. coli*
331 (sensitive to mannose) and *Salmonella* spp., which leads to elimination of these bacteria with the
332 digesta flow instead of binding a mucosal receptor (Ofek et al., 1977; Spring et al., 2000; Parks et
333 al., 2001; Fernandez et al., 2002).

334

335 Oligosaccharide beta-glucans of yeast cell wall origin are thought to stimulate performance
336 because of their immunomodulatory effects. Their main action is to enhance phagocytosis and
337 proliferation of monocytes and macrophages (Novak and Vetvicka, 2009). As macrophages play a
338 crucial role in immunomodulation, the interaction of glucans with macrophages can have huge
339 effects in the host. Recent reviews elaborate on the action of glucans on immune stimulation
340 (Schepetkin and Quinn, 2006; Novak and Vetvicka, 2009). Studies with animals have documented
341 significant health benefits from using immune modulating β -1,3/1,6-glucan (from yeast cell walls)
342 as a feed ingredient to protect animals against micro-organisms (Williams et al., 1996).

343

344 One approach for future research will be to examine the combination of both probiotics and
345 prebiotics (as 'synbiotics'), which may be defined as a mixture of probiotics and prebiotics that
346 beneficially affects the host by improving the survival and persistence of living microbial dietary
347 supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating

348 the metabolism of one or a limited number of health-promoting bacteria (Patterson and Burkholder,
349 2003). This combination would thus combine substrate and bacteria.

350

351 *Herbs and etheric oils*

352 Many plants have beneficial multifunctional properties derived from their specific bio-active
353 components. Biologically active constituents of plants are mostly secondary metabolites, such as
354 terpenoids (mono-and sesquiterpenes, steroids, etc.), phenolics (tannins), glycosides and alkaloids
355 (present as alcohols, aldehydes, ketones, esters, ethers, lactones, etc.). There is a lot of variation in
356 composition due to biological factors (plant species, growing location, and harvest conditions),
357 manufacturing (extraction/distillation, stabilization) and storage conditions (light, temperature,
358 oxygen tension and time). The challenge is to identify and quantify the multitude of actions and
359 claims improving feed utilisation, animal physiology and health status.

360

361 Because of possible ‘synergy’ between constituents, it remains unclear which components of
362 etheric oil products may stimulate the endogenous digestive enzymes, act as an antioxidant,
363 antimicrobial agent, or immunomodulator. There are experimental data showing the in vitro anti-
364 microbial effects with respective MIC-values and spectrum of activity (see, for example, Penalver
365 et al., 2005; Fu et al., 2007; Barbosa et al., 2009). According to Adams (1999) the antimicrobial
366 activity is rather weak for ginger and pepper, medium for cumin (p-cymene), coriander (lialol),
367 oregano (carvacrol), rosemary (cineol), sage (cineol) and thyme (thymol) and strong for clove
368 (eugenol), mustard (allylisothiocyanate), cinnamon (cinnamaldehyde) and garlic (allicin).

369

370 **Regulations concerning feed additives for animal use**

371 A zootechnical additive is any additive other than feed material and pre-mixtures used to
372 affect favourably the performance of animals in good health or used to affect favourably the
373 environment. The category 'zootechnical additive' can be further divided into four functional
374 groups: (1) digestibility enhancers; these are substances which, when fed to animals, increase the
375 digestibility of the diet, through action on target feed materials; (2) gut flora stabilisers; these are
376 micro-organisms or other chemically defined substances, which, when fed to animals, have a
377 positive effect on the gut flora; (3) substances which favourably affect the environment; (4) other
378 zootechnical additives.

379

380 EC Regulation 1831/2003 will establish a Community procedure for authorising the placing
381 on the market and use of feed additives and to lay down rules for the supervision and labelling of
382 feed additives and pre-mixtures in order to provide the basis for the assurance of a high level of
383 protection of human health, animal health and welfare, environment and users' and consumers'
384 interests in relation to feed additives, whilst ensuring the effective functioning of the internal
385 market. This Regulation will not apply to processing aids and veterinary medicinal products as
386 defined in Directive 2001/82/EC³, with the exception of coccidiostats and histomonostats used as
387 feed additives. However, prebiotics (inulin, fructo-mannanligosaccharides, yeast cell walls rich in
388 beta-glucans) or short and medium chain fatty acids are considered as feedstuffs and not as feed
389 additives and so fall under the scope of Regulation 0767/2009⁴ concerning the trade of animal
390 feeds. However, the classification of a product as either a feedstuff or a feed additive remains
391 unclear because of differences in the relative impact of technological processing.

392

393 Botanical or herbal extracts, flavours and etheric oils (EOs) now fall within the scope of EC
394 Regulation 1831/2003. In general, unprocessed herbs are regarded as feed materials and do not need

³ See: http://www.echamp.eu/fileadmin/user_upload/Regulation/Directive_2001-82-EC_-_Consolidated_Version_.pdf

⁴ See: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:229:0001:0028:EN:PDF>

395 authorisation. Notified plant extracts or components are included in the Community Register of
396 Feed Additives⁵. This register has only informative purposes and does not replace Community legal
397 acts. The Community legal acts concerning the authorisation of each additive entered in the
398 Register constitute the legal basis for the placing on the market and use of additive concerned. This
399 means that before November 2010, a complete scientific dossier for each notified EO or component
400 shall be submitted to EFSA (European Food Safety Authority) which provides guidance on
401 scientific data needed to carry out a safety assessment for botanical agents⁶. After a full evaluation
402 by EFSA, a positive outcome and authorisation by the Standing Committee on the Food Chain and
403 Animal Health (SCFCAH), these EOs can be used legally in the EU in animal nutrition⁷. The actual
404 status of the EFSA evaluation of the scientific dossier can be checked at the Register of Questions⁸.

405

406 **Economical considerations**

407 The general health status determining the performance of broilers is multifactorial. Good
408 management relies on continuous monitoring of the flock for health status and performance.
409 Monitoring of the health status requires regular necropsies with determinations of lesion scores, and
410 identification of pathogens including the make-up of an antibiogram. Monitoring of performance
411 requires information such as feed intake and weight gain, flock uniformity, litter score, climatic and
412 other conditions. This should, at least in theory, provide a view of the cost of the ban in terms of
413 decreased growth rate, higher morbidity and mortality, increased condemnations, and depressed
414 yield.

415

416 The return-on-investment for alternatives to AGPs will depend on both the biological impact
417 and the actual market price. It must take into account the fact that the feed cost of these alternatives

⁵ See: http://ec.europa.eu/food/food/animalnutrition/feedadditives/registeradditives_en.htm

⁶ http://www.efsa.europa.eu/cs/BlobServer/Guidance_of_Panel/sc_op_ej1249_botanicals_en.pdf

⁷ http://ec.europa.eu/food/food/animalnutrition/feedadditives/index_en.htm

⁸ <http://registerofquestions.efsa.europa.eu/roqFrontend/questionsList.jsf>

418 is quite variable, ranging from (€/ton⁹): 2-3 for enzymes, 3-12 for organic acids, 4-7 for probiotics,
419 9-17 for immunostimulants, 2-15 for oligosaccharides, 3-25 for herbs and etheric oils (in
420 comparison with 1-2 and 2-4 for respectively feed antibiotics and anticoccidials, depending on dose
421 and type of product). The net economic effect will depend on several factors including the effects
422 on performance levels and the cost of any technologies adopted to compensate for the termination
423 of AGPs, and may be offset by the benefits of increased consumer confidence.

424

425 Unlike with pigs, termination of AGPs in European poultry has not resulted in increases in
426 therapeutic use of antimicrobials largely because of the continuing use of ionophores for the
427 prophylaxis of coccidiosis (Grave et al., 2006). Indeed both chemical and ionophore anticoccidials
428 are almost universally used in the broiler industry. Without these drugs (e.g. during the withdrawal
429 period), birds will become infested and damage to the intestinal epithelial cells will provide further
430 opportunities for ‘subclinical’ necrotic enteritis and performance problems. Ionophore
431 anticoccidials also have an additional antibacterial potential. In article 11 of the European Council
432 regulation 1831/2003, the European Union states that the use of anticoccidials as feed additives
433 should be phased out by December 2012. However, in 2008, the European Commission submitted a
434 report on the use of these substances as feed additives and existing alternatives to the Council and
435 the European Parliament (COM/2008/0233¹⁰). In this report, the European Commission clearly
436 recommends maintaining the current legislation and allowing the use of ionophore anticoccidials as
437 feed additives because of the lack of alternatives and to preserve the economic viability of the
438 poultry industry.

439

440 AGP replacers seem to be adequate when other control measures that beneficially affect gut
441 health are also applied. The question remains whether the current AGP replacers have enough

⁹ € = approx. £0.89 , \$1.43, as at 07 January 2010.

442 potential to replace both AGPs and anticoccidials. There is a need to set and then to meet standards
443 for the replacement of antibiotic compounds in poultry, in terms of product type, identification of
444 suppliers, poultry response criteria, regulatory status and veterinary definition (Rosen, 2003).

445

446 **Conclusions**

447 Alternatives for AGPs are only of practical significance when they improve animal performance at
448 levels comparable to AGPs. Microbiota modulating and immunomodulatory compounds have
449 potential and are used as feedstuff or feed additives. Enzymes, acids, pre- and probiotics and herbs
450 or etheric oils are some examples of product classes which are used as alternatives for AGPs.
451 Within each product class, numerous products are on the market, and while some products clearly
452 have potential, for others the efficacy is not clear. There is thus an urgent need to describe the
453 mechanism of action of these compounds in a scientific way and to set and meet standards for AGP
454 alternatives for broilers.

455

456 **Conflict of interest statement**

457 None of the authors of this paper has a financial or personal relationship with other
458 people or organisations that could inappropriately influence or bias the content of the paper.

459

460

461 **References**

462 Adams, C., 1999. *Nutricines: Food components in health and nutrition*. Nottingham University
463 Press, UK.

464

465 Adams, M.R., Hall, C.J., 1988. Growth inhibition of food-borne pathogens by lactic acid and acetic
466 acids and their mixtures. *International Journal of Food Science and Technology* 23, 287-292.

467

468 Annison, G., 1991. Relationship between the levels of soluble nonstarch polysaccharides and the
469 apparent metabolisable energy of wheats assayed in broiler chickens. *Journal of Agricultural Food
470 Chemistry* 39, 1252-1256.

471

¹⁰ See:

[http://www.ipex.eu/ipex/webdav/site/myjahiasite/groups/CentralSupport/public/2008/COM_2008_0233/COM_COM\(2008\)0233_EN.pdf](http://www.ipex.eu/ipex/webdav/site/myjahiasite/groups/CentralSupport/public/2008/COM_2008_0233/COM_COM(2008)0233_EN.pdf)

472 Barbosa, L.N., Rall, V.L., Fernandes, A.A., Ushimaru, P.I., da Sliva Probst, I., Fernandes, A.Jr.,
473 2009. Essential oils against foodborne pathogens and spoilage bacteria in minced meat. *Foodborne*
474 *Pathogen Diseases* 6: 725-728.

475

476 Bedford, M.R., Classen, H.L., 1992. Reduction of intestinal viscosity through manipulation of
477 dietary rye and pentosanase concentration is effected through changes in the carbohydrate
478 composition of the intestinal aqueous phase and results in improved growth rate and food
479 conversion efficiency of broiler chicks. *Journal of Nutrition* 122, 560-569.

480

481 Bjerrum, L., Engberg, R., Leser, T.D., Jensen, B.B., Finster, K., Pedersen, K., 2006. Microbial
482 community composition of the ileum and cecum of broiler chickens as revealed by molecular and
483 culture-based techniques. *Poultry Science* 85, 1151-1164.

484

485 Bordin, M., D'Atri, F., Guillemot, L., Citi, S., 2004. Histone deacetylase inhibitors up-regulate the
486 expression of tight junction proteins. *Molecular Cancer Research* 2, 692-701.

487

488 Brennan, J., Skinner, J., Barnum, D.A., Wilson, J., 2003. The efficacy of bacitracin methylene
489 disalicylate when fed in combination with narasin in the management of necrotic enteritis in broiler
490 chickens. *Poultry Science* 82, 360-363.

491

492 Castanon, J.I., 2007. History of the use of antibiotic growth promoters in European poultry feeds.
493 *Poultry Science* 86, 2466-2471.

494

495 Choct, M., Hughes, R.J., Wang, J., Bedford, M.R., Morgan, A.J., Annison, G., 1996. Increased
496 small intestinal fermentation responsible for the anti-nutritive activity of non-starch polysaccharides
497 in chickens. *British Poultry Science* 37, 609-621.

498

499 Choct, M., Hughes, R.J., Bedford, M.R., 1999. Effects of a xylanase on individual bird variation,
500 starch digestion throughout the intestine, and ileal and caecal volatile fatty acid production in
501 chickens fed wheat. *British Poultry Science* 40, 419-422.

502

503 Choct, M., 2002. Non-starch polysaccharides: effect on nutritive value. In : McNab, J.M., Boorman,
504 K.N. (Eds.), *Poultry feedstuffs*. CABI Publishing, New York, US.

505

506 Coates, M.E., Fuller, R., Harrison, G.F., Lev, M., Suffolk, S.F., 1963. A comparison of the growth
507 of chicks in the Gustafsson germ-free apparatus and in a conventional environment, with and
508 without dietary supplements of penicillin. *British Journal of Nutrition* 17, 141-150.

509

510 Coon, C.N., Leske, K.L., Akavanichan, O., Cheng, T.K. 1990. Effect of oligosaccharide free
511 soybean meal on true metabolisable energy and fiber digestion in adult roosters. *Poultry Science* 69,
512 787-793.

513

514 Dalmaso G., Nguyen H.T., Yan Y., Charrier-Hisamuddin L., Sitaraman S.V., Merlin D., 2008.
515 Butyrate transcriptionally enhances peptide transporter PepT1 expression and activity. *PLoS ONE*.
516 3: e2476.

517

518 Dänicke, S., Vahjen, W., Simon, O., Jeroch, H., 1999. Effects of dietary fat and xylanase
519 supplementation to rye-based broiler diets on selected bacteria groups adhering to the intestinal
520 epithelium, on transit time of feed, and on nutrient digestibility. *Poultry Science* 78, 1292-1299.

521

522 Dibner, J.J., Richards, J.D., 2005. Antibiotic growth promoters in agriculture: history and mode of
523 action. *Poultry Science* 84, 634-643.
524

525 Duncan, S.H., Louis, P., Flint, H.J., 2004. Lactate-utilizing bacteria, isolated from human feces that
526 produce butyrate as a major fermentation product. *Applied Environmental Microbiology* 70, 5810-
527 5817.
528

529 Durst, L., 1996. Inclusion of fructo- and galacto-oligosaccharides in broiler diets. *Archives fur*
530 *Geflügelkunde* 60, 160-164.
531

532 Elwinger, K., Teglöf, B. 1991. Performance of broiler chickens as influenced by a dietary enzyme
533 complex with and without antibiotic supplementation. *Archives fur Geflügelkunde* 55, 69-73.
534

535 Feighner, S.D., Dashkevicz, M.P., 1987. Sub-therapeutic levels of antibiotics in poultry feeds and
536 their effects on weight gain, feed efficiency, and bacterial cholytaurine hydrolase activity. *Applied*
537 *and Environmental Microbiology* 53, 331-336.
538

539 Fernandez, F., Hinton, M., Van Gils, B. 2002. Dietary mannan-oligosaccharides and their effect on
540 chicken caecal microflora in relation to *Salmonella* Enteritidis colonisation. *Avian Pathology* 31,
541 49-58.
542

543 Fu, Y., Zu, Y., Chen, L., Shi, X., Wang, Z., Sun, S., Efferth, T., 2007. Antimicrobial activity of
544 clove and rosemary oils alone and in combination. *Phytotherapy Research* 21, 989-994.
545

546 Fuller, R. 1992. History and development of probiotics. In: Fuller, R. (Ed.), *Probiotics - The*
547 *scientific basis*, Chapman & Hall, London.
548

549 George, B.A., Quarles, C.L., Fagerberg, D.J., 1982. Virginiamycin effects on controlling necrotic
550 enteritis infections in chickens. *Poultry Science* 61, 447-450.
551

552 Gibson, G.R., Roberfroid, M.B., 1995. Dietary modulation of the human colonic microbiota:
553 Introducing the concept of prebiotica. *Journal of Clinical Nutrition* 125, 1401-1412.
554

555 Grave, K., Jensen, V.F., Odensvik, K., Wierup, M., Bangen, M., 2006. Usage of veterinary
556 therapeutic antimicrobials in Denmark, Norway and Sweden following termination of antimicrobial
557 growth promoter use. *Preventive Veterinary Medicine* 75, 132-132.
558

559 Hedemann, M.S., Theil, P.K., Bach-Knudsen, K.E., 2009. The thickness of the intestinal mucous
560 layer in the colon of rats fed various sources of non-digestible carbohydrates is positively correlated
561 with the pool of SCFA but negatively correlated with the proportion of butyric acid in digesta.
562 *British Journal of Nutrition* 102, 117-125.
563

564 Hodin, R., 2000. Maintaining gut homeostasis: the butyrate-NF-kappaB connection.
565 *Gastroenterology* 118, 798-801.
566

567 Hofacre, C.L., Froyman, R., Gautrias, B., George, B., Goodwin, M.A., Brown, J., 1998. Use of
568 Aviguard and other intestinal bioproducts in experimental *Clostridium perfringens*-associated
569 necrotizing enteritis in broiler chickens. *Avian Diseases* 42, 579-584.
570

571 Huisman, M.M., Brül, L.P., Thomas-Oates, J.E., Haverkamp, J., Schols, H.A., Voragen, A.G. 2001.
572 The occurrence of internal (1-5)-linked arabinofuranose and arabinopyranose residues in
573 arabinogalactan side chains from soybean pectic substances. *Carbohydrate Research* 330, 103-114.
574

575 Humphrey, B. D., Klasing, K.C., 2003. Modulation of nutrient metabolism and homeostasis by the
576 immune system. In: *Proceedings of the European Symposium on Poultry Nutrition*, Lillehammer,
577 Norway.
578

579 Iji, P.A., Tivey, D.R., 1998. Natural and synthetic oligosaccharides in broiler chicken diets. *World*
580 *Poultry Science Journal* 54, 129-143.
581

582 Jackson, M.E., Anderson, D.M., Hsiao, H.Y., Mathis, G.F., Fodge, D.W., 2003. Beneficial effect of
583 β -mannanase feed enzyme on performance of chicks challenged with *Eimeria* sp. and *Clostridium*
584 *perfringens*. *Avian Diseases* 47, 759-763.
585

586 Kalliomäki, M., Salminen, S., Isolauri, E., 2008. Positive interactions with the microbiota :
587 probiotics. *Advances in Experimental Medical Biology* 635, 57-66.
588

589 Knarreborg, A., Lauridsen, C., Engberg, R.M., Jensen, S.K., 2004. Dietary antibiotic growth
590 promoters enhance the bioavailability of alpha-tocopheryl acetate in broilers by altering lipid
591 absorption. *Journal of Nutrition* 134, 1487-1492.
592

593 La Ragione, R.M., Narbad, A., Gasson, M.J., Woodward, M.J., 2004. *In vivo* characterization of
594 *Lactobacillus johnsonii* FI9785 for use as defined competitive exclusion agent against bacterial
595 pathogens in poultry. *Letters in Applied Microbiology* 38, 197-205.
596

597 Leske, K.L., C.J. Jevne, Coon, C.N., 1991. Extraction methods for removing soybean alpha
598 galactosides and improving true metabolisable energy for poultry. *Animal Feed Science and*
599 *Technology* 41, 73-78.
600

601 Lu, J. Idris, U., Harmon, B., Hofacre, C., Maurer, J.J., Lee, M.D., 2003. Diversity and succession of
602 the intestinal bacterial community of the maturing broiler chicken. *Applied and Environmental*
603 *Microbiology* 69, 6816-6824.
604

605 Maczulak, A.E., M.J. Wolin, Miller, T.L., 1993. Amounts of viable anaerobes, methanogens and
606 bacterial fermentation products in faeces of rats fed high fiber or fiber-free diets. *Applied and*
607 *Environmental Microbiology* 59, 657-662.
608

609 Madsen, K.L., Cornish, A., Soper, P., McKaigney, C., Jijon, H., Yachimec, C, Doyle, J., Jewell, L.,
610 De Simone, C., 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier
611 function. *Gastroenterology* 121, 580-591.
612

613 Mariadason, J.M., Barkla, D.H., Gibson, P.R., 1997. Effect of short-chain fatty acids on paracellular
614 permeability in Caco-2 intestinal epithelium model. *American Journal of Physiology* 272, G705-
615 712.
616

617 Ng, S.G., Hart, A.L., Kamm, M.A., Stagg, A.J., Knight, S.C., 2009. Mechanism of action of
618 probiotics: recent advances. *Inflammatory Bowel Diseases* 15: 300-310.
619

620 Niewold, T.A., 2007. The nonantibiotic anti-inflammatory effect of antimicrobial growth
621 promoters, the real mode of action? A hypothesis. *World Poultry Science Journal* 86: 605-609.

622
623 Novak, M., Vetvicka, V., 2008. Beta-glucans, history, and the present: immunomodulatory aspects
624 and mechanisms of action. *Journal of Immunotoxicology* 5, 47-57.
625
626 Nurmi, E., Rantala, M., 1973. New aspects of *Salmonella* infection in broiler production. *Nature*
627 241, 210-211.
628
629 Ofek, I., Mirelman, D., Sharon, N., 1977. Adherence of *Escherichia coli* to human mucosal cells
630 mediated by mannose receptors. *Nature (London)* 265, 623-625.
631
632 Parks, C.W., Grimes, J.L., Ferket, P.R., Fairchild, A.S., 2001. The effect of mannan-
633 oligosaccharides, Bambermycin, and Virginiamycin on performance of Large White male mate
634 turkeys. *Poultry Science* 80, 718-723.
635
636 Patten, J.D., Waldroup, P.W., 1988. Use of organic acids in broiler diets. *Poultry Science*. 67, 1178-
637 1182.
638
639 Patterson, J.A., Burkholder, K.M., 2003. Application of prebiotics and probiotics in poultry
640 production. *Poultry Science* 82, 627-631.
641
642 Pedroso, A.A., Menten, J.F., Lambais, M.R., Racanicci, A.M., Longo, F.A., Sorbara, J.O., 2006.
643 Intestinal bacterial community and growth performance of chickens fed diets containing antibiotics.
644 *Poultry Science* 85: 747-752.
645
646 Penalver, P., Huerta, B., Borge, C., Astorga, R., Romero, R., Perea, A., 2005. Antimicrobial activity
647 of five essential oils against origin strains of the Enterobacteriaceae family. *APMIS* 113, 1-6.
648
649 Peng, L., He, Z., Chen, W., Holzman, I.R., Lin, J., 2007. Effects of butyrate on intestinal barrier
650 function in a Caco-2 cell monolayer model of intestinal barrier. *Pediatrics Research* 61, 37-41.
651
652 Ramirez-Farias, C., Slezk, K., Fuller, Z., Duncan, A., Holtrop, G., Louis, P., 2009. Effect on inulin
653 on the human gut microbiota : stimulation of *Bifidobacterium adolescentis* and *Faecalibacterium*
654 *prausnitzii*. *British Journal of Nutrition* 101, 541-550.
655
656 Salanitro, J.P., Blake, I.G., Muirhead, P.A., Maglio, M., Goodman, J.R., 1978. Bacteria isolated
657 from the duodenum, ileum and caecum of young chicks. *Applied and Environmental Microbiology*
658 35, 782-790.
659
660 Schauber, J., Svanholm, C., Termén, S., Iffland, K., Menzel, T., Scheppach, W., Melcher, R.,
661 Agerbeth, B., Lühns, H., Gudmundsson, G.H., 2003. Expression of the cathelicidin LL-37 is
662 modulated by short-chain fatty acids in colonocytes: relevance of signalling pathways. *Gut* 52, 735-
663 741.
664
665 Schepetkin, I.A., Quinn, M.T., 2006. Botanical polysaccharides: macrophage immunomodulation
666 and therapeutic potential. *International Immunopharmacology* 6, 317-333.
667
668 Schols, H.A., Voragen, A.G., Colquhoun, I.J. 1994. Isolation and characterization of
669 rhamnogalacturan oligomers, liberated during degradation of pectic hairy regions by
670 rhamnogalacturonase. *Carbohydrate Research* 256, 97-111.
671

672 Sherman, P.M., Ossa, J.C., Johnson-Henry, K., 2009. Unravelling mechanisms of action of
673 probiotics. *Nutrition Clinical Practice* 21, 10-14.
674

675 Smits, C.H.M. Annison, G., 1996. Non-starch polysaccharides in broiler nutrition – towards a
676 physiologically valid approach to their determination. *World Poultry Science Journal* 52, 203-221.
677 Snyder, D.L., Westmann, B.S., 1987. Growth rate of male germfree Wistar rats fed ad libitum or
678 restricted natural ingredient diet. *Laboratory Animal Science* 37, 320-325.
679

680 Spring, P., Wenk, C., Dawson, K.A., Newman, K.E., 2000. The effects of dietary mannan-
681 oligosaccharides on caecal parameters and the concentrations of enteric bacteria in the caeca of
682 *Salmonella*-challenged broiler chicks. *Poultry Science* 79, 205-211.
683

684 Teirlynck, E., Bjerrum, L., Eeckhaut, V., Huyghebaert, G., Pasmans, F., Haesebrouck, F., Dewulf,
685 J., Ducatelle, R., Van Immerseel, F., 2009. The cereal type in feed influences gut wall morphology
686 and intestinal immune cell infiltration in broiler chickens. *British Journal of Nutrition* in press.
687

688 Thompson, J.L., Hinton, M., 1997. Antibacterial activity of formic and propionic acids in the diet of
689 hens on *Salmonella* in the crop. *British Poultry Science* 38, 59-65.
690

691 Timbermont, L., 2009. A contribution to the pathogenesis and treatment of *Clostridium perfringens*
692 associated necrotic enteritis in broilers. PhD thesis, Faculty of Veterinary Medicine, Ghent
693 University.
694

695 Van Craeyveld, V., Holopainen, U., Selinheimo, E., Poutanen, K., Delcour, J., Courtin, C.M. 2009.
696 Extensive dry ball milling of wheat and rye bran leads to in situ production of arabinoxylan
697 oligosaccharides through nanoscale fragmentation. *Journal of Agricultural Food Chemistry* 57,
698 8467-8473.
699

700 Van Der Wielen, P.W., Biesterveld, S., Notermans, S., Hofstra, H., Urlings, B.A., Van Knapen, F.,
701 2000. Role of volatile fatty acids in development of the cecal microflora in broiler chickens during
702 growth. *Applied and Environmental Microbiology* 71, 2206-2207.
703

704 Van Der Wielen, P.W., Keuzenkap, D.A., Lipman, L.J., Van Knapen, F., Biesterveld, S., 2002.
705 Spatial and temporal variation of the intestinal bacterial community in commercially raised broiler
706 chickens during growth. *Microbial Ecology* 44, 286-293.
707

708 Van Immerseel, F., Russell, J.B., Flythe, M.D., Gantois, I., Timbermont, L., Pasmans, F.,
709 Haesebrouck, F., Ducatelle, R., 2006. The use of organic acids to combat *Salmonella* in poultry: a
710 mechanistic explanation of the efficacy. *Avian Pathology* 35, 182-188.
711

712 Waldroup, A.L., Skinner, J.T., Hierholzer, R.E., Waldroup, P.W., 1993. An evaluation of fructo-
713 oligosaccharide in diets for broiler chickens and effects on salmonellae contamination of carcasses.
714 *Poultry Science* 72, 643-650.
715

716 Wierup, M., 2001. The Swedish experience of the 1986 ban of antimicrobial growth promoters,
717 with special reference to animal health, disease prevention, productivity, and usage of
718 antimicrobials. *Microbial Drug Resistance* 7, 183-190.
719

720 Williams, D.L., Mueller, A., Browder, W., 1996. Glucan-based macrophage stimulators-A review
721 of their anti-infective potential. *Clinical Immunotherapy* 5, 392-399.
722

723 Wise M.G., Siragusa, G.R., 2007. Quantitative analysis of the intestinal bacterial community in
724 one- to three-week-old commercially reared broiler chickens fed conventional or antibiotic-free
725 vegetable-based diets. *Journal of Applied Microbiology* 102, 1138-1149.
726
727
728
729
730